🇺🇸 FDA
Pipeline program

Lenalidomide

ACCRU-LY-2101

Phase 2 small_molecule active

Quick answer

Lenalidomide for Recurrent Mantle Cell Lymphoma is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Recurrent Mantle Cell Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials